Stereotaxis CEO Invited as Keynote Speaker at Robotic Surgery & Enabling Technologies Summit 2021
12 Abril 2021 - 10:05AM
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, announces
that David Fischel, Chairman and CEO, will serve as the keynote
speaker at the Robotic Surgery & Enabling Technologies Virtual
Summit 2021. The presentation will take place on Thursday, April
15, 2021.
Mr. Fischel will focus his discussion on the
current clinical and technological frontiers of robotic
surgery.
“We are excited for David to share his broad
perspective on what the robotic surgery community has accomplished
and the significant areas of opportunity ahead of us,” says Dr.
Emir Osmanagic, Chairman of The Summit and Director of Digital
Surgery at Johnson & Johnson.
“I am honored to be able to join Dr. Osmanagic
and The Summit,” says Mr. Fischel. “We are experiencing a golden
period of progress for robotic technology in medicine, with
advances in robotics and the digitization of surgery having an
increasingly positive impact on patient care and healthcare
systems.”
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. The core components of Stereotaxis’
systems have received regulatory clearance in the United States,
European Union, Japan, Canada, China, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute “forward-looking” statements, usually containing the
words “believe,” “estimate,” “project,” “expect” or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to continue to manage expenses
and cash burn rate at sustainable levels, continued acceptance of
the Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare policy in the United
States, including changes in government reimbursement of
procedures, dependence upon third-party vendors, timing of
regulatory approvals, the impact of the recent coronavirus
(COVID-19) pandemic and our response to it, and other risks
discussed in the Company's periodic and other filings with the
Securities and Exchange Commission. By making these forward-looking
statements, the Company undertakes no obligation to update these
statements for revisions or changes after the date of this release.
There can be no assurance that the Company will recognize revenue
related to its purchase orders and other commitments in any
particular period or at all because some of these purchase orders
and other commitments are subject to contingencies that are outside
of the Company's control. In addition, these orders and commitments
may be revised, modified, delayed or canceled, either by their
express terms, as a result of negotiations, or by overall project
changes or delays.
Company Contacts:
David L. FischelChairman and Chief Executive
Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Stereotaxis (AMEX:STXS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024